# US 2017/0253561 A1 · Benzylamine Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253561 A1
- Document ID: US20170253561A1
- Status: Published application
- Kind: A1
- Application number: 15/602,688
- Filed: 2017-05-23
- Published: 2017-09-07
- Earliest claimed: 2013-01-08
- Assignees: Kalvista Pharmaceuticals Limited
- Applicants: Kalvista Pharmaceuticals Limited
- Inventors: Christine Elizabeth Allan; Andrzej Roman Batt; Rebecca Louise Davie; Hannah Joy Edwards; David Michael Evans; Stephen John Pethen
- Web page: https://patentgrep.com/patent/US20170253561A1

## CPC

- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 249/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

## Claims

### Claim 1

A method of treating a disease or condition in which plasma kallikrein activity is implicated, comprising administration to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
wherein:
V is C or N such that the aromatic ring containing V is phenyl or pyridine;
R2 is absent when V is N; or, when present, R2 is H, alkyl, alkoxy, CN, halo or CF3;
R1 and R3 are, independently, H, alkyl, alkoxy, CN, halo or CF3;
W, X, Y and Z are, independently, C, N, O, or S, such that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle;
R5, R6 and R7 are, independently, absent, H, alkyl, halo, aryl, heteroaryl, or CF3;
P is —C(R10)(R11)NH2;
R8 and R9 are, independently, H or alkyl, or may together form a cycloalkyl ring;
R10 and R11 are, independently, H or alkyl, or may together form a cycloalkyl ring or a cyclic ether;
A is N-linked morpholine, aryl, or heteroaryl; and wherein
alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl is optionally substituted with 1 or 2 substituents which are, independently, (C1-C6)alkoxy, OH, CN, CF3, —COOR12, —CONR12R13, H(CH2)1-3CON(R12)(CH2)1-3—, fluoro and —NR12R13;
cycloalkyl is a monocyclic saturated hydrocarbon of between 3 and 7 carbon atoms; wherein cycloalkyl is optionally substituted with a substituent which is alkyl, alkoxy or NR12R13;
a cyclic ether is a monocyclic saturated hydrocarbon of between 4 and 7 carbon atoms, wherein one of the ring carbons is replaced by an oxygen atom;
alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy is optionally substituted with 1 or 2 substituents which are, independently, aryl, OH, CN, CF3, —COOR12, —CONR12R13, fluoro, or NR12R13;
aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, -morpholinyl, -piperidinyl, heteroaryl, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryl, —COOR12, —CONR12R13, —(CH2)1-3—NR14R15, CF3 and NR12R13;
arylb is phenyl, biphenyl or naphthyl, which is optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, —COOR12, —CONR12R13, CF3, or NR12R13;
heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O; heteroaryl is optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, —(CH2)1-3-aryl, heteroarylb, —COOR12, —CONR12R13, CF3 or NR12R13;
heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O; wherein heteroarylb is optionally substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, aryl, —(CH2)1-3-aryl, —COOR12, —CONR12R13, CF3 or NR12R13;
R12 and R13 are, independently, H or alkyl; or R12 and R13 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocyclic ring which is saturated or unsaturated with 1 or 2 double bonds;
R14 and R15 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered heterocyclic ring which is saturated or unsaturated with 1 or 2 double bonds, and optionally is oxo substituted;
wherein,
when R5, R6 and R7 are absent or H, then:
either
R10 and R11 together form a cycloalkyl ring or a cyclic ether;
or
A is aryl and aryl is phenyl, biphenyl or naphthyl substituted with 1, 2 or 3 substituents which are, independently, OH, heteroaryl, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryl, —COOR12, —CONR12R13, or —(CH2)3—NR14R15; wherein,
arylb is phenyl, biphenyl or naphthyl, wherein arylb is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, —COOR12, —CONR12R13, CF3 or NR12R13; and
heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O, wherein heteroaryl is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, halo, CN, aryl, morpholinyl, piperidinyl, —(CH2)1-3-aryl, heteroarylb, —COOR12, —CONR12R13, CF3 or —NR12R13;
or
A is heteroaryl and heteroaryl is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S and O, wherein heteroaryl is substituted with 1, 2 or 3 substituents which are, independently, aryl, —(CH2)1-3-aryl, heteroarylb, —COOR12, or —CONR12R13; wherein,
aryl is phenyl, biphenyl or naphthyl, wherein aryl is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, OH, halo, CN, morpholinyl, piperidinyl, heteroaryl, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryl, —COOR12, —CONR12R13, —COR12R13, —(CH2)1-3—NR14R15, CF3 or —NR12R13; and
heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members which are, independently, N, NR12, S or O, wherein heteroarylb is substituted with 1, 2 or 3 substituents which are, independently, alkyl, alkoxy, halo, CN, morpholinyl, piperidinyl, aryl, —(CH2)1-3-aryl, —COOR12, —CONR12R13, CF3 or NR12R13;
or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof;
wherein the disease or condition in which plasma kallikrein activity is implicated is cerebral haemorrhage, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery, or bleeding from post operative surgery.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one of R5, R6 and R7 is alkyl, halo, aryl, heteroaryl or CF3.

### Claim 3 (depends on 1)

The method of claim 1, wherein A is:

### Claim 4 (depends on 1)

The method of claim 1, wherein A is:

### Claim 5 (depends on 1)

The method of claim 1, wherein R5, R6 and R7 are absent or H; and A is:

### Claim 6 (depends on 1)

The method of claim 1, wherein, X is N and W, Y and Z are C.

### Claim 7 (depends on 6)

The method of claim 6, wherein R5 is H, and R6 and R7 are methyl.

### Claim 8 (depends on 1)

The method of claim 1, wherein, X and Y are N and W and Z are C.

### Claim 9 (depends on 1)

The method of claim 1, wherein, X, Y and Z are N and W is C.

### Claim 10 (depends on 1)

The method of claim 1, wherein R8 and R9 are H.

### Claim 11 (depends on 1)

The method of claim 1, wherein:
W is C;
X is N;
Y is C;
Z is C;
R5 is H;
R6 and R7 are CH3;
R8 and R9 are H; and
R10 and R11 are both H or together form a cyclopropane ring.

### Claim 12 (depends on 1)

The method of claim 1, wherein V is C.

### Claim 13 (depends on 1)

The method of claim 1, wherein R1 is alkyl, alkoxy, CN, halo or CF3.

### Claim 14 (depends on 1)

The method of claim 1, wherein R1 is alkyl.

### Claim 15 (depends on 1)

The method of claim 1, wherein R3 is alkyl.

### Claim 16 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is:
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-(1-amino-cyclopropyl)-benzylamide;
2,5-Dimethyl-1-(6-phenyl-pyridin-2-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;
1-[2-(3-Fluoro-phenyl)-thiazol-4-ylmethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;
2,5-Dimethyl-1-(2-thiophen-3-yl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid (6-aminomethyl-pyridin-3-ylmethyl)-amide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-fluoro-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-chloro-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-trifluoromethyl-benzylamide;
2,5-Dimethyl-1-(2-phenyl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methoxy-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide;
1-[4-(3,5-Dimethyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-benzylamide;
2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;
2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide;
2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
2,5-Dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-3-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-imidazole-4-carboxylic acid 4-aminomethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-imidazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2-methyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H-imidazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-1H[1,2,3]triazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide;
1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrrole-2-carboxylic acid 4-aminomethyl-benzylamide;
5-Methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-[4-(4-Methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-3-fluoro-2-methyl-benzylamide;
3-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
5-Methyl-1-(2-methyl-quinolin-6-ylmethyl)-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-(2-Methyl-quinolin-6-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
1-(2-Pyrrolidin-1-yl-pyridin-4-ylmethyl)-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid 4-aminomethyl-2,6-dimethyl-benzylamide;
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the disease or condition in which plasma kallikrein activity is implicated is cerebral haemorrhage.

### Claim 18 (depends on 1)

The method of claim 1, wherein the disease or condition in which plasma kallikrein activity is implicated is cerebral haemorrhage in hyperglycemic patients.

### Claim 19 (depends on 1)

The method of claim 1, wherein the disease or condition in which plasma kallikrein activity is implicated is disseminated intravascular coagulation.

### Claim 20 (depends on 1)

The method of claim 1, wherein the disease or condition in which plasma kallikrein activity is implicated is blood coagulation during cardiopulmonary bypass surgery.

### Claim 21 (depends on 1)

The method of claim 1, wherein the disease or condition in which plasma kallikrein activity is implicated is bleeding from post-operative surgery.
